Salomon & Ludwin’s Myriad Genetics MYGN Stock Holding History

Salomon & Ludwin’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-637	Closed	-$3.91K	–	2157
2025 Q4	$3.91K	Sell	637 -63	-9%	-$457	﹤0.01%	1859
2025 Q3	$9.7K	Buy	+700	New	+$4.16K	﹤0.01%	1323

Other funds holding MYGN

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

GCM

Glenview Capital Management New York $5.49B AUM 46.89% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Salomon & Ludwin's MYGN Position: Q1 2026 in Review

Salomon & Ludwin sold out of Myriad Genetics (MYGN) in Q1 2026, closing a stake of 637 shares — an estimated $3.91K sold.

Salomon & Ludwin first reported a position in MYGN in Q3 2025 and held it in 2 quarters. The position peaked at $9.7K in Q3 2025. 203 funds tracked by Wall St. Rank hold MYGN as of Q1 2026.

Salomon & Ludwin reported no remaining Myriad Genetics position as of Q1 2026 after selling out during the quarter.
Salomon & Ludwin sold 637 Myriad Genetics shares in Q1 2026, an estimated $3.91K.
Salomon & Ludwin first reported a position in Myriad Genetics in Q3 2025 and held it in 2 quarters.
Salomon & Ludwin's Myriad Genetics position peaked at $9.7K in Q3 2025.
203 funds tracked by Wall St. Rank held Myriad Genetics as of Q1 2026.

Based on Salomon & Ludwin's 13F filing for Q1 2026, filed 11 May 2026.